Kanada - angličtina - Health Canada

pharmaceutical partners of canada inc - cefuroxime (cefuroxime sodium) - powder for solution - 7.5g - cefuroxime (cefuroxime sodium) 7.5g - second generation cephalosporins

Spojené státy - angličtina - NLM (National Library of Medicine)

wg critical care, llc - cefuroxime sodium (unii: r8a7m9my61) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 750 mg - cefuroxime for injection, usp is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: - lower respiratory tract infections, including pneumonia, caused by streptococcus pneumoniae, haemophilus influenzae (including ampicillin-resistant strains), klebsiella spp., staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), streptococcus pyogenes , and escherichia coli . - urinary tract infections caused by escherichia coli and klebsiella spp. - skin and skin structure infections caused by staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), streptococcus pyogenes , escherichia coli, klebsiella spp., and enterobacter spp. - septicemia caused by staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), streptococcus pneumoniae, escherichia coli, haemophilus influenzae (including ampicillin-resistant strains), and klebsiella spp. - meningitis

Spojené státy - angličtina - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 125 mg in 5 ml - note: cefuroxime axetil tablets and cefuroxime axetil for oral suspension are not bioequivalent and are not substitutable on a milligram-per-milligram basis (see clinical pharmacology). cefuroxime axetil for oral suspension is indicated for the treatment of pediatric patients 3 months to 12 years of age with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. the safety and effectiveness of cefuroxime axetil for oral suspension in the treatment of infections other than those specifically listed below have not been established either by adequate and well-controlled trials or by pharmacokinetic data with which to determine an effective and safe dosing regimen. - pharyngitis/tonsillitis caused by streptococcus pyogenes. note: the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. cefuroxime axetil for oral suspensio

Spojené státy - angličtina - NLM (National Library of Medicine)

medvantx, inc. - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs, cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. note: cefuroxime axetil tablets and cefuroxime axetil for oral suspension are not bioequivalent and are not substitutable on a milligram-per-milligram basis (see clinical pharmacology) cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below:  1. pharyngitis/tonsillitis caused by streptococcus pyogenes. note: the usual dr

Izrael - angličtina - Ministry of Health

a.l. medi-market ltd. - cefuroxime as sodium - powder for solution or suspension for injection or infusion - cefuroxime as sodium 750 mg/vial - cefuroxime - cefuroxime be pharma 750 mg is indicated for the treatment of the infections listed below in adults and children, including neonates (from birth)•community acquired pneumonia•acute exacerbations of chronic bronchitis•complicated urinary tract infections, including pyelonephritis•soft-tissue infections: cellulitis, erysipelas and wound infections•intra-abdominal infections•prophylaxis against infection in gastrointestinal (including oesophageal), orthopaedic, cardiovascular, and gynaecological surgery (including caesarean section)•nose infections for example, sinusitis•septic arthritis

Filipíny - angličtina - FDA (Food And Drug Administration)

a. johnson pharma int'l corp - cefuroxime (as sodium) - powder for injection im/iv - 750mg

Filipíny - angličtina - FDA (Food And Drug Administration)

one pharma company, inc. - cefuroxime (as sodium) - powder for injection (iv/im) - 750mg

Filipíny - angličtina - FDA (Food And Drug Administration)

medical generics mktg co., - cefuroxime (as sodium) - powder for injection im/iv - 750mg

Filipíny - angličtina - FDA (Food And Drug Administration)

health saver pharma inc - cefuroxime (as sodium) - powder for injection im/iv - 750mg

Filipíny - angličtina - FDA (Food And Drug Administration)

qualifirst health inc - cefuroxime (as sodium) - powder for injection im/iv/iv infusion - 1.5g